Business
Table 1: M&A snapshot (November 2007-October 2008)
Buyer Country Target Country Focus/assets Total value Details
3i (private equity) UK Alpharma’s API business Norway APIs $395 million
Access Pharmaceuticals US MacroChem US oncology $9 million
Actavis Iceland Zhejiang Chiral Medicine Chemicals China APIs N/A
Adamis Pharmaceuticals US Cellegy Pharmaceuticals US viral diseases N/A
Adipogen Pharmaceuticals Australia Verva Pharmaceuticals Australia metabolic disease N/A Chemgenex
Pharmaceuticals
Autogen
Research
subsidiary
Advent International US LaborMed Pharma Romania generics, €123 million
(private equity) cardiovascular, CNS
Aida Pharmaceuticals China Jiangsu Institute of Microbiology China microbiology N/A
Aisling Capital, US Esperion Therapeutics US dyslipidaemia N/A
Alta Partners,
Domain Associates
Algorithme Pharma Canada Simbec Research UK CRO N/A
Alliance Boots UK Athos Farma Brazil wholesaler N/A 25% stake
Amarin UK Ester Neurosciences Israel neuroscience $32 million
Amneal Pharmaceuticals US Interpharm US generics N/A
Antisoma UK Xanthus Pharmaceuticals US oncology £26.8 million
Anzag Germany Armila Lithuania wholesaler N/A majority stake
Arch Pharmalabs India Avon Organics India APIs Rs290 million 63% stake
($7.3 million)
Arch Pharmalabs India Benzochem Lifesciences India APIs, intermediates N/A majority stake
Ark Therapeutics UK Lymphatix Finland VEGF products €2.3 million
Astellas Pharma Japan Agensys US oncology antibodies $387 million
Avant Immunotherapeutics US Celldex Therapeutics US immunotherapies $75 million
AVI Biopharma US Ercole Biotech US RNA $9 million
Bayer Healthcare Germany Sagmel’s OTC business US OTC N/A
Bayer Healthcare Germany Direvo Biotech Germany protein engineering €210 million
Belupo Croatia Farmavita Bosnia & wholesaler N/A
Herzegovina
Biocon India Axicorp Germany manufacturing, €30 million 70% stake
distribution
Biomedica Foscama Spain Pliva’s Spanish operations Spain generics N/A
Industria Chimico-
Farmaceutica
Biovail Canada Prestwick Pharmaceuticals US CNS $100 million
Boehringer Ingelheim Germany Actimis US respiratory, $515 million
inf_l ammatory
Bristol-Myers Squibb US Kosan Biosciences US oncology $190 million
BTG UK Protherics UK antibodies £218.1 million
Celgene US Pharmion US haematology, $2.9 billion
oncology
Celldex Therapeutics US Avant Immunotherapeutics US oncology, infectious $115 million
diseases,
inf_l ammatory
Chiltern UK Clinical Trial Management Services US CRO N/A
Chiltern UK Drug Development Solutions UK Phase I unit N/A
China Aoxing China Shijiazhuang Lerentang China pain Yuan80 million
Pharmaceutical Pharmaceutical ($10.8 million)
Clinical Data US Adenosine Therapeutics US various $36.2 million
CSL Australia Talecris Biotherapeutics US plasma $3.1 billion
Cubist Pharmaceuticals US Illumigen Biosciences US hepatitis C $341.5 million
Cyclacel Pharmaceuticals US Align Pharmaceuticals US oncology $3.8 million
Cypress Bioscience US Proprius Pharmaceuticals US pain, arthritis $75 million
CytRx US Innovive Pharmaceuticals US oncology, $21.3 million
haematology
Daiichi Sankyo Japan U3 Pharma Germany oncology biologics €150 million
Daiichi Sankyo Japan Ranbaxy Laboratories India generics $3.4-4.6 billion
Dara Biosciences US Point Therapeutics US Nasdaq listing N/A
Dr Reddy’s Laboratories India Dowpharma’s small molecule UK custom services N/A
business
Dr Reddy’s Laboratories India Jet Generici Italy generics N/A
ECI Partners UK Premier Research Group UK CRO £60.1 million management
(private equity) buyout
Eczacibasi Pharmaceuticals Turkey Monrol Nuclear Products Turkey radiopharmaceuticals €30 million 50% stake
Egis Hungary Anpharm’s generic products Poland generics PLN55 million
($22.6 million)
Eisai Japan MGI Pharma US oncology, acute care $3.9 billion
Eusa Pharma UK Cytogen US oncology, pain $22.6 million
Evotec Germany Renovis US CNS €62 million
Fresenius Kabi Germany Dabur Pharma India oncology generics Rs8.8 billion
($178 million)
Fresenius Kabi Germany APP Pharmaceuticals US manufacturing, $3.7 billion
distribution
20
www.scripnews.com/supplements Scrip 100
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128